Prism marketview highlights altimmune's positive topline results in obesity drug trial

New york, ny, december 05, 2023 – prism marketview, a leading provider of unbiased market insight and company news, highlights altimmune, inc. (nasdaq: alt) which has reported positive topline results from its 48-week momentum phase 2 obesity trial of pemvidutide. the company's study enrolled 391 subjects with obesity and at least one comorbidity.
ALT Ratings Summary
ALT Quant Ranking